Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $6.75

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus recommendation of “Hold” from the eight brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $6.75.

Several equities analysts have issued reports on INO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th.

Trending Headlines about Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright issued mixed but slightly constructive estimate revisions — it modestly raised Q1–Q3 and FY2026 EPS forecasts (FY now -$1.05) while lowering its Q4 2026 view; the firm kept a Neutral rating, so analyst action is only a modest support for the stock.
• Neutral Sentiment: Multiple law firms are issuing reminders about the April 7, 2026 lead‑plaintiff deadline — procedural notices can drive short-term trading volume as eligible shareholders consider joining litigation, but they do not by themselves change merits of the case. INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Pomerantz LLP filed a securities class action against Inovio and certain officers covering purchases between Oct. 10, 2023 and Dec. 26, 2025 — an active filing raises potential liability, discovery risk, and management distraction that investors typically view as negative. Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO
• Negative Sentiment: Several national firms (Rosen, Faruqi & Faruqi, Levi & Korsinsky, Holzer & Holzer, Gross Law Firm, etc.) are actively soliciting clients and encouraging lead‑plaintiff motions — the broad legal outreach increases the likelihood of aggregated claims and sustained headline risk. LEVI & KORSINSKY, LLP: APRIL 7, 2026 — DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION

Inovio Pharmaceuticals Stock Down 1.2%

Inovio Pharmaceuticals stock opened at $1.66 on Monday. The business has a fifty day moving average of $1.65 and a two-hundred day moving average of $2.03. The firm has a market cap of $114.69 million, a P/E ratio of -0.99 and a beta of 1.70. Inovio Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.68. The company had revenue of ($0.07) million during the quarter, compared to analysts’ expectations of $0.33 million. Equities analysts expect that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. MCF Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $26,000. SG Americas Securities LLC purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth $27,000. Stephens Inc. AR purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth $32,000. Focus Partners Wealth acquired a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.